AEON Biopharma appoints CFO and general counsel
AEON Biopharma, a startup biopharma company aiming to pursue the therapeutic toxin market, hired two executives—Chris Carr as chief financial officer and Scott Akamine as general counsel. Carr brings over 25 years of financial experience in the pharmaceutical and biotech industries. Carr most recently served as CFO of Dendreon Pharmaceuticals.
Akamine has over 10 years of legal experience in guiding corporate growth legal stategy. Most recently, Akamine was associate general counsel at CoreLogic. Before that, Akamine worked in-house at Incipio and Allergan, and was also an attorney at Latham & Watkins.
“AEON Biopharma is uniquely positioned as the only company focused solely on the therapeutic uses of neurotoxins at a time where this already large market is set for incredible growth and I am pleased that Chris Carr and Scott Akamine have joined our management team to help lead our successful trajectory in the market,” said Marc Forth, AEON Biopharma’s president and CEO. “Scott’s extensive expertise in legal and regulatory strategy will be vital in supporting AEON Biopharma’s client relationships and overall growth.”